Clinical Trial Update: Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of Tenalisib (RP6530) in relapsed/refractory chronic lymphocytic leukemia, sponsored by Rhizen Pharmaceuticals …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Tenalisib (tenalisib)

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2021-07-22